Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Intelence

INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13

HOS-119741 · Präparat HOS-095005

12 OESTROGEN-BASED CONTRACEPTIVES Ethinylestradiol ethinylestradiol The combination of 0.035 mg once daily AUC ↑ 1.22 (1.13-1.31) oestrogen- and/or Norethindrone Cmin ↔ 1.09 (1.01-1.18) progesterone-based 1 mg once daily Cmax ↑ 1.33 (1.21-1.46) contraceptives and norethindrone INTELENCE can be used AUC ↔ 0.95 (0.90-0.99) without dose adjustment. Cmin ↓ 0.78 (0.68-0.90) Cmax ↔ 1.05 (0.98-1.12) etravirine AUC ↔a Cmin ↔a Cmax ↔a HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS Ribavirin Not studied, but no interaction expected based The combination of on the renal elimination pathway of ribavirin. INTELENCE and ribavirin can be used without dose adjustments. Daclatasvir Not studied. Co-administration of etravirine Co-administration of with daclatasvir may decrease daclatasvir INTELENCE and daclatasvir concentrations. is not recommended. Elbasvir/grazoprevir Not studied. Co-administration of etravirine Co-administration is with elbasvir/grazoprevir may decrease elbasvir contraindicated (see and grazoprevir concentrations, leading to section 4.3). reduced therapeutic effect of elbasvir/grazoprevir. HERBAL PRODUCTS St John’s wort Not studied. St John’s wort is expected to Combination not (Hypericum perforatum) decrease the plasma concentrations of recommended. etravirine. HMG CO-A REDUCTASE INHIBITORS Atorvastatin atorvastatin The combination of 40 mg once daily AUC ↓ 0.63 (0.58-0.68) INTELENCE and Cmin ND atorvastatin can be given Cmax ↑ 1.04 (0.84-1.30) without any dose 2-OH-atorvastatin adjustments, however, the AUC ↑ 1.27 (1.19-1.36) dose of atorvastatin may Cmin ND need to be altered based on Cmax ↑ 1.76 (1.60-1.94) clinical response. etravirine AUC ↔ 1.02 (0.97-1.07) Cmin ↔ 1.10 (1.02-1.19) Cmax ↔ 0.97 (0.93-1.02) Fluvastatin Not studied. No interaction between pravastatin Dose adjustments for these Lovastatin and etravirine is expected. HMG Co-A reductase Pravastatin Lovastatin, rosuvastatin and simvastatin are inhibitors may be necessary. Rosuvastatin CYP3A4 substrates and co-administration with Simvastatin etravirine may result in lower plasma concentrations of the HMG Co-A reductase inhibitor. Fluvastatin, and rosuvastatin are metabolised by CYP2C9 and co-administration with etravirine may result in higher plasma concentrations of the HMG Co-A reductase inhibitor. H2-RECEPTOR ANTAGONISTS Ranitidine etravirine INTELENCE can be 150 mg twice daily AUC ↓ 0.86 (0.76-0.97) co-administered with Cmin ND H2-receptor antagonists Cmax ↓ 0.94 (0.75-1.17) without dose adjustments.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) daclatasvir (HOS-119742) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) ribavirin (HOS-088127) grazoprevir (HOS-108815) ranitidine (HOS-085660) norethindrone (HOS-088136) pravastatin (HOS-086306)